Last reviewed · How we verify
TEV-48574 Dose Regiment B — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
TEV-48574 Dose Regiment B (TEV-48574 Dose Regiment B) — Teva Branded Pharmaceutical Products R&D LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TEV-48574 Dose Regiment B TARGET | TEV-48574 Dose Regiment B | Teva Branded Pharmaceutical Products R&D LLC | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TEV-48574 Dose Regiment B CI watch — RSS
- TEV-48574 Dose Regiment B CI watch — Atom
- TEV-48574 Dose Regiment B CI watch — JSON
- TEV-48574 Dose Regiment B alone — RSS
Cite this brief
Drug Landscape (2026). TEV-48574 Dose Regiment B — Competitive Intelligence Brief. https://druglandscape.com/ci/tev-48574-dose-regiment-b. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing